Patents by Inventor Alan J. Bitonti

Alan J. Bitonti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20160222112
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: December 30, 2015
    Publication date: August 4, 2016
    Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20160222109
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: December 29, 2015
    Publication date: August 4, 2016
    Applicants: Dyax Corp., Biogen Hemophilia Inc.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20160222111
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: December 30, 2015
    Publication date: August 4, 2016
    Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20160222110
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: December 29, 2015
    Publication date: August 4, 2016
    Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use Thereof
    Publication number: 20160199455
    Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: December 9, 2015
    Publication date: July 14, 2016
    Applicant: Biogen Hemophilia Inc.
    Inventors: Jennifer A. DUMONT, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert Peters
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20160194397
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: December 31, 2015
    Publication date: July 7, 2016
    Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • Antibodies to FeRn and uses thereof
    Patent number: 9260520
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: February 16, 2016
    Assignees: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James McGivney, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
    Patent number: 9241978
    Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: January 26, 2016
    Assignee: BIOGEN HEMOPHILIA INC.
    Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert Peters
  • CELL LINE EXPRESSING SINGLE CHAIN FACTOR VIII POLYPEPTIDES AND USES THEREOF
    Publication number: 20150191526
    Abstract: The present invention provides cell lines for producing single chain FVIII polypeptides, e.g., chimeric single chain FVIII polypeptides, methods of producing single chain FVIII polypeptides, single chain FVIII polypeptides, and methods of treating Hemophilia A with a single chain Factor VIII polypeptide.
    Type: Application
    Filed: July 5, 2013
    Publication date: July 9, 2015
    Applicant: Biogen Idec MA Inc.
    Inventors: Susan Low, Jennifer A. Dumont, Alan J. Bitonti
  • Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
    Patent number: 9050318
    Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: December 6, 2010
    Date of Patent: June 9, 2015
    Assignee: Biogen Idec Hemophilia Inc.
    Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert Peters
  • Clotting Factor-Fc Chimeric Proteins to Treat Hemophilia
    Publication number: 20150044207
    Abstract: The Invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a hemostatic disorder comprising administering a therapeutically effective amount of a chimeric protein wherein the chimeric protein comprises at least one clotting factor and at least a portion of an immunoglobulin constant region.
    Type: Application
    Filed: July 17, 2014
    Publication date: February 12, 2015
    Applicant: Biogen Idec Hemophilia Inc.
    Inventors: Daniel S. RIVERA, Robert T. Peters, Alan J. Bitonti
  • Immunoglobulin chimeric monomer-dimer hybrids
    Patent number: 8932830
    Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: January 13, 2015
    Assignee: Biogen Idec Hemophilia, Inc.
    Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, James McGivney, Susan C. Low
  • Immunoglobulin chimeric monomer-dimer hybrids
    Patent number: 8900827
    Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: December 2, 2014
    Assignee: Biogen Idec Hemophilia, Inc.
    Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, James McGivney, Susan C. Low
  • FACTOR VIII CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF
    Publication number: 20140294821
    Abstract: The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells
    Type: Application
    Filed: July 6, 2012
    Publication date: October 2, 2014
    Applicant: Biogen Idec Hemophilia inc.
    Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron Mckinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert Peters
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20140248287
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: January 30, 2014
    Publication date: September 4, 2014
    Applicants: SYNTONIX PHARMACEUTICALS, INC., DYAX CORP.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James Stattel, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • Clotting factor-Fc chimeric proteins to treat hemophilia
    Patent number: 8815250
    Abstract: The invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a hemostatic disorder comprising administering a therapeutically effective amount of a chimeric protein wherein the chimeric protein comprises at least one clotting factor and at least a portion of an immunoglobulin constant region.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: August 26, 2014
    Assignee: Biogen Idec Hemophilia Inc.
    Inventors: Daniel S. Rivera, Robert T. Peters, Alan J. Bitonti
  • Fc receptor binding proteins
    Patent number: 8815246
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: August 26, 2014
    Assignees: Dyax Corp., Syntonix Pharmaceuticals, Inc.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James Stattel, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use Thereof
    Publication number: 20130274194
    Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: March 11, 2013
    Publication date: October 17, 2013
    Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert Peters
  • Clotting factor-fc chimeric proteins to treat hemophilia
    Patent number: 8449884
    Abstract: The invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a hemostatic disorder comprising administering a therapeutically effective amount of a chimeric protein wherein the chimeric protein comprises at least one clotting factor and at least a portion of an immunoglobulin constant region.
    Type: Grant
    Filed: November 18, 2010
    Date of Patent: May 28, 2013
    Assignee: Syntonix Pharmaceuticals, Inc.
    Inventors: Daniel S. Rivera, Robert T. Peters, Alan J. Bitonti
  • Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use Thereof
    Publication number: 20130108629
    Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: December 6, 2010
    Publication date: May 2, 2013
    Applicant: BIOGEN IDEC HEMOPHILIA INC.
    Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert Peters